Envestnet Asset Management Inc Hutchmed (China) LTD Transaction History

Envestnet Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$12.08 - $18.56 $374 - $575	-31 Reduced 0.2%	15,111 $253,000
Q4 2023 Feb 13, 2024	BUY	$16.25 - $20.23 $246,057 - $306,322	15,142 New	15,142 $274,000
Q2 2023 Aug 04, 2023	BUY	$10.78 - $17.73 $166,022 - $273,059	15,401 New	15,401 $184,000
Q2 2022 Aug 03, 2022	SELL	$8.59 - $20.77 $176,816 - $427,529	-20,584 Reduced 54.65%	17,078 $216,000
Q1 2022 May 04, 2022	BUY	$15.52 - $35.65 $4,531 - $10,409	292 Added 0.78%	37,662 $713,000
Q4 2021 Feb 04, 2022	BUY	$28.89 - $35.33 $37,730 - $46,140	1,306 Added 3.62%	37,370 $1.31 Million
Q3 2021 Oct 07, 2021	BUY	$35.66 - $42.94 $135,365 - $163,000	3,796 Added 11.76%	36,064 $1.32 Million
Q2 2021 Aug 04, 2021	BUY	$23.7 - $39.27 $90,273 - $149,579	3,809 Added 13.38%	32,268 $1.27 Million
Q1 2021 May 04, 2021	BUY	$27.01 - $36.8 $55,478 - $75,587	2,054 Added 7.78%	28,459 $804,000
Q4 2020 Feb 02, 2021	BUY	$27.51 - $34.36 $366,570 - $457,847	13,325 Added 101.87%	26,405 $845,000
Q3 2020 Oct 09, 2020	BUY	$25.8 - $34.61 $77,271 - $103,656	2,995 Added 29.7%	13,080 $422,000
Q2 2020 Jul 08, 2020	BUY	$17.65 - $28.05 $178,000 - $282,884	10,085 New	10,085 $278,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.